AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01964755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
Study NCT01964755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
Study NCT03709680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
Study NCT03709680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
Study NCT03709680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
Study NCT03709680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Study NCT03709680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Study NCT03709680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Study NCT03709680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Study NCT02118376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5ug bid,Subcutaneous injection
Study NCT03805126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Legal Partnership
Description: With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
Study NCT03805126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care includes consultation with a social worker and a community health worker.
Study NCT03805126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care includes consultation with a social worker and a community health worker.
Study NCT01486576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (Hydroxyethyl starch 130/0,4)
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study NCT01964755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
Study NCT01486576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9 mg/ml
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study NCT04461821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time SESI-MS breath analysis
Description: Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
Study NCT01964755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is optional and will be administered to study participants, per study protocol.
Study NCT02495571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cough Assessment in ALS Patients
Description: 1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)
Study NCT02495571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cough Assessment in ALS Patients
Description: 1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral capsaicin
Description: Subjects will drink a solution with capsaicin
Study NCT00621062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Ligation of the GSV
Description: Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
Study NCT00621062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser Ablation
Description: Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
Study NCT00621062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
Study NCT00621062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foam Sclerotherapy
Description: Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
Study NCT04192344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021
Description: ABSK021 oral capsule
Study NCT04461821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Off-line breath analysis
Description: In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
Study NCT02664493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
Study NCT01695772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU based doublet chemotherapy
Description: Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
Study NCT01695772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oral capsaicin
Description: Subjects will drink a solution with capsaicin
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Description: Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Topical capsaicin
Description: Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal capsaicin
Description: Capsaicin cream will be applied to the nostril
Study NCT04461821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intranasal capsaicin
Description: Capsaicin cream will be applied to the nostril
Study NCT01701310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
Study NCT03511846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Irrigation
Description: Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
Study NCT01701310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate
Description: (Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
Study NCT04461821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva analysis
Description: During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
Study NCT04461821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine analysis
Description: During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
Study NCT00951821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent treatment
Description: Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
Study NCT00951821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent treatment only
Description: Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
Study NCT01268293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
Study NCT00716976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: Given IV
Study NCT00716976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: examination
Description: Patients undergo audiological assessments periodically
Study NCT02804763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion, 0,9% saline
Study NCT02804763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol (DZP)
Description: Solution for infusion
Study NCT00067756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-PBA
Description: During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
Study NCT02181933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT02181933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine (ZDV)
Study NCT02181933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine (3TC)
Study NCT02599584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: precritical staff
Description: free pre critical scenario team staff
Study NCT04858893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CoMDA associated with Neural Net 91 classificator
Study NCT01915316 — intervention group
Intervention type: OTHER
Intervention: prostate biopsy
Description: Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
Study NCT00959751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXN-188
Description: 200 mg capsules, 600 mg, PRN
Study NCT00883883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
Study NCT00883883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
Study NCT00959751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg capsules with no active ingredient designed to match the NXN-188 capsules
Study NCT03511846 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cold Water Irrigation
Description: Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
Study NCT03511846 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Medical Air
Description: Subjects will be exposed to medical air
Study NCT01554787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb Astragalus membranaceus
Description: Astragalus membranaceus(AM)at a rate of 2.8g three times per day
Study NCT01554787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: at a rate of 2.8g three times per day
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Flow Oxygen
Description: Subjects will be exposed to oxygen gas between 1-9 L/min
Study NCT05446493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: * Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.~* Penile color Doppler ultrasound examination before and after treatment
Study NCT03511846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Flow Oxygen
Description: Subjects will be exposed to oxygen gas between 10-25 L/min
Study NCT04291261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Uvadex
Description: Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
Study NCT04544722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jianfei Kangfu Cao
Description: The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
Study NCT04544722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lung rehabilitation training
Description: The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
Study NCT02681666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Sessions will be spent with patients discussing the FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and how to use this diet to treat their Irritable Bowel Syndrome.
Study NCT03059368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new bone fixation plate with screw
Description: Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
Study NCT00879177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
Study NCT00879177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
Study NCT02857088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: olfactory assessment
Description: determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
Study NCT02857088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: image visualization
Description: 20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
Study NCT02857088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychophysiological assessment
Description: during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
Study NCT03100149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7046015
Description: RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
Study NCT03100149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7046015
Description: RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
Study NCT03100149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RO7046015 placebo will be administered to all participants in the indicated arm.
Study NCT01464970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Both Superficial Inferior Artery and Vein Clamped
Description: Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
Study NCT01464970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Inferior Epigastric Vessels both unclamped
Description: Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
Study NCT02681666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Irritable Bowel Syndrome eating awareness training
Description: A type of meditation about their eating habits.
Study NCT00879177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral therapy
Description: confirmed negative smoking status at different time points
Study NCT04818775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemaClear
Description: HemaClear Model A